fluorouracil has been researched along with Rhabdomyosarcoma in 21 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Rhabdomyosarcoma: A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)
| Excerpt | Relevance | Reference |
|---|---|---|
| " A series of new anti-cancer pyrimidine acyclonucleoside-like compounds were designed and synthesized by structural modifications of 5-fluorouracil, a drug which causes considerable cell toxicity and morbidity, and we evaluated their applicability for differentiation therapy in human rhabdomyosarcoma cells." | 7.70 | GR-891: a novel 5-fluorouracil acyclonucleoside prodrug for differentiation therapy in rhabdomyosarcoma cells. ( Aránega, A; Arena, N; Campos, J; Espinosa, A; Gallo, MA; Gómez, JA; Marchal, JA; Melguizo, C; Prados, J, 1999) |
| " Recently, by structural modifications of 5-fluorouracil (5-FU), we synthesized a new pyrimidine acyclonucleoside-like compound, 1-¿[3-(3-chloro-2-hydroxypropoxy)-1-methoxy]propyl¿-5-fluorouracil (QF-3602), which showed in rhabdomyosarcoma cells a low toxicity and time-dependent growth inhibition." | 7.70 | Modulation of myogenic differentiation in a human rhabdomyosarcoma cell line by a new derivative of 5-fluorouracil (QF-3602). ( Aránega, A; Aránega, AE; Arena, N; Campos, J; Espinosa, A; Gallo, MA; Gómez, JA; Marchal, JA; Melguizo, C; Prados, J, 2000) |
| "Irinotecan and etoposide were combined using the (d x 5)2 i." | 5.29 | Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma. ( Cheshire, PJ; Hallman, JD; Houghton, JA; Houghton, PJ; Li, Y; Luo, X; Lutz, L, 1996) |
| " Adenocarcinoma related to diethylstilbestrol exposure in utero is a recently recognized type of vaginal lesion, and melanoma and sarcoma occur rarely in the vagina." | 3.66 | Malignant tumors of the vagina. Classification and approach to treatment. ( Gerbie, MV, 1983) |
| "Irinotecan and etoposide were combined using the (d x 5)2 i." | 1.29 | Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma. ( Cheshire, PJ; Hallman, JD; Houghton, JA; Houghton, PJ; Li, Y; Luo, X; Lutz, L, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (61.90) | 18.7374 |
| 1990's | 4 (19.05) | 18.2507 |
| 2000's | 4 (19.05) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Domínguez, JF | 1 |
| Marchal, JA | 4 |
| Correa, A | 1 |
| Carrillo, E | 2 |
| Boulaiz, H | 2 |
| Aránega, A | 4 |
| Gallo, MA | 4 |
| Espinosa, A | 4 |
| Rodríguez-Serrano, F | 1 |
| Peran, M | 1 |
| Vélez, C | 1 |
| Domínguez, J | 1 |
| Gómez-Vidal, JA | 1 |
| Campos, J | 3 |
| Lancaster, LD | 1 |
| Ewy, GA | 1 |
| Gerbie, MV | 1 |
| Houghton, JA | 1 |
| Cheshire, PJ | 1 |
| Hallman, JD | 1 |
| Lutz, L | 1 |
| Luo, X | 1 |
| Li, Y | 1 |
| Houghton, PJ | 1 |
| Prados, J | 2 |
| Melguizo, C | 2 |
| Gómez, JA | 2 |
| Arena, N | 2 |
| Aránega, AE | 1 |
| Theys, J | 1 |
| Landuyt, W | 1 |
| Nuyts, S | 1 |
| Van Mellaert, L | 1 |
| van Oosterom, A | 1 |
| Lambin, P | 1 |
| Anné, J | 1 |
| Black, K | 1 |
| Hanna, SS | 1 |
| Langer, B | 1 |
| Jirsch, DW | 1 |
| Rider, WD | 1 |
| Livingston, RB | 1 |
| Merrin, CE | 1 |
| Murphy, GP | 1 |
| Lubec, G | 1 |
| Szalay, S | 1 |
| Slavik, M | 1 |
| Inedjian, JM | 1 |
| Thomassin, JM | 1 |
| Danoy, MC | 1 |
| Sermet, M | 1 |
| Geunoun, A | 1 |
| Balis, FM | 1 |
| Gillespie, A | 1 |
| Belasco, J | 1 |
| Reaman, GH | 1 |
| Ettinger, LJ | 1 |
| Murphy, RF | 1 |
| Doherty, K | 1 |
| Jeffries, S | 1 |
| Horowitz, ME | 1 |
| Poplack, DG | 1 |
| Furusaka, T | 1 |
| Kida, A | 1 |
| Iizuka, N | 1 |
| Kikuchi, K | 1 |
| Tomita, H | 1 |
| Visser, GW | 1 |
| Gorree, GC | 1 |
| Braakhuis, BJ | 1 |
| Herscheid, JD | 1 |
| Baumgart, J | 1 |
| Zhukovskaya, NV | 1 |
| Anisimov, VN | 1 |
| Snow, GB | 1 |
| Sindram, PJ | 1 |
| Duprez, A | 1 |
| Robert, J | 1 |
| Kissel, P | 1 |
| Sugiura, H | 1 |
| Inukai, A | 1 |
2 reviews available for fluorouracil and Rhabdomyosarcoma
| Article | Year |
|---|---|
Cardiac consequences of malignancy and their treatment.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cyclophosphamide; Fluorouracil; Heart; Heart Neo | 1984 |
Chemotherapy of solid tumors. Recent advances.
Topics: Adult; Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Bronchogenic; Carcinom | 1976 |
1 trial available for fluorouracil and Rhabdomyosarcoma
| Article | Year |
|---|---|
Clinical studies with DTIC (NSC-45388) in various malignancies.
Topics: Adult; Carmustine; Child; Clinical Trials as Topic; Dacarbazine; Drug Evaluation; Drug Therapy, Comb | 1976 |
18 other studies available for fluorouracil and Rhabdomyosarcoma
| Article | Year |
|---|---|
Synthesis and evaluation of new 5-fluorouracil antitumor cell differentiating derivatives.
Topics: Antineoplastic Agents; Cell Differentiation; Cell Division; Drug Screening Assays, Antitumor; Flow C | 2003 |
5-fluorouracil derivatives induce differentiation mediated by tubulin and HLA class I modulation.
Topics: Antimetabolites, Antineoplastic; Cell Differentiation; Cell Line; Fluorouracil; Gene Expression Regu | 2007 |
Malignant tumors of the vagina. Classification and approach to treatment.
Topics: Adenocarcinoma; Adolescent; Adult; Carcinoma in Situ; Carcinoma, Squamous Cell; Child; Diethylstilbe | 1983 |
Evaluation of irinotecan in combination with 5-fluorouracil or etoposide in xenograft models of colon adenocarcinoma and rhabdomyosarcoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colonic Neopl | 1996 |
GR-891: a novel 5-fluorouracil acyclonucleoside prodrug for differentiation therapy in rhabdomyosarcoma cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Division; Drug | 1999 |
Modulation of myogenic differentiation in a human rhabdomyosarcoma cell line by a new derivative of 5-fluorouracil (QF-3602).
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Differentiation; Fibronectins; Fluorou | 2000 |
Specific targeting of cytosine deaminase to solid tumors by engineered Clostridium acetobutylicum.
Topics: Animals; Antifungal Agents; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Clos | 2001 |
Management of carcinoma of the extrahepatic bile ducts.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Bile Duct Neoplasms; Carcinoma, Squamous Cell; Child; Commo | 1978 |
Chemotherapy of urogenital cancer.
Topics: Adenocarcinoma; Adult; Child; Cyclophosphamide; Dactinomycin; Doxorubicin; Female; Fluorouracil; Hum | 1976 |
[5-fluorouracil inhibits bacterial collagenase and the collagenolytic system of a human rhabdomyosarcoma].
Topics: Cells, Cultured; Clostridium; Collagen; Drug Evaluation, Preclinical; Enzyme Activation; Fluorouraci | 1979 |
[Extraskeletal pharyngolaryngeal Ewing's sarcoma. Apropos of a case].
Topics: Adult; Cisplatin; Combined Modality Therapy; Diagnosis, Differential; Fluorouracil; Humans; Immunohi | 1991 |
Phase II trial of sequential methotrexate and 5-fluorouracil with leucovorin in children with sarcomas.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Chromato | 1990 |
Combination chemotherapy with CDDP, 5-FU and PEP in head and neck malignant tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Squamous Cell; Ci | 1986 |
An optimized synthesis of 18F-labelled 5-fluorouracil and a reevaluation of its use as a prognostic agent.
Topics: Animals; Colonic Neoplasms; Drug Screening Assays, Antitumor; Fluorouracil; Humans; Mice; Mice, Nude | 1989 |
Carcinogenesis and aging. VIII. Effect of host age on tumour growth, metastatic potential, and chemotherapeutic sensitivity to 1.4-benzoquinone-guanylhydrazonethiosemicarbazone (ambazone) and 5-fluorouracil in mice and rats.
Topics: Adenocarcinoma; Aging; Animals; Antineoplastic Agents; Cell Division; Female; Fluorouracil; Leukemia | 1988 |
Intra-arterial infusion chemotherapy in head and neck cancer. A clinical and experimental study.
Topics: Animals; Carotid Artery, External; Catheterization; Chemotherapy, Cancer, Regional Perfusion; Diseas | 1973 |
[Action of 5-fluoro-uracil on the synthesis of DNA by a methylcholanthrene-induced rhabdomyosarcoma in the C57-Br mouse].
Topics: Animals; DNA, Neoplasm; Fluorouracil; Methylcholanthrene; Mice; Rhabdomyosarcoma; Sarcoma, Experimen | 1966 |
[Case of sarcoma botryoides of the bladder in a child].
Topics: Female; Fluorouracil; Humans; Infant; Rhabdomyosarcoma; Urinary Bladder Neoplasms; Urography | 1968 |